Furthermore, we demonstrated that inhibition of LSEC VCAM1 can ameliorate not only NASH-related liver fibrosis but also liver fibrosis in a more generalized context by employing CCl4-induced liver fibrosis model. Here, VCAM1 is linked to metabolic dysfunction-associated steatohepatitis.